USPH
U.S. Physical Therapy, Inc. NYSE Listed May 29, 1992$63.32
+0.76%
vs $62.84
Mkt Cap $960.9M
52w Low $59.00
12.6% of range
52w High $93.16
50d MA $67.48
200d MA $77.89
P/E (TTM)
44.6x
EV/EBITDA
10.8x
P/B
1.2x
Debt/Equity
0.9x
ROE
8.3%
P/FCF
15.8x
RSI (14)
47.10
ATR (14)
$2.30
Beta
1.35
50d MA
$67.48
200d MA
$77.89
Avg Volume
249.3K
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2021, it operated 591 clinics in 39 states; and managed 35 physical therapy practice facilities. The company was founded in 1990 and is based in Houston, Texas.
1300 West Sam Houston Parkway South · Houston, TX 77042 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.55 | 0.46 | -16.4% | 73.65 | -8.5% | -19.9% | +0.5% | +0.2% | +2.4% | -1.2% | — |
| Feb 25, 2026 | AMC | 0.67 | 0.67 | +0.0% | 81.68 | -3.0% | -2.9% | +4.6% | +0.1% | +0.3% | +1.0% | — |
| Nov 5, 2025 | AMC | 0.67 | 0.66 | -1.5% | 88.05 | -6.6% | -11.9% | -4.8% | -0.8% | +1.5% | -2.5% | — |
| Aug 6, 2025 | AMC | 0.71 | 0.81 | +14.1% | 72.69 | +9.4% | +15.2% | +4.7% | -1.1% | +0.9% | +1.2% | — |
| May 7, 2025 | AMC | 0.46 | 0.48 | +4.3% | 70.96 | -2.3% | -0.1% | +4.5% | +4.4% | -0.2% | +0.1% | — |
| Feb 26, 2025 | AMC | 0.69 | 0.65 | -5.8% | 87.72 | -6.4% | -6.0% | -1.7% | -1.7% | -0.3% | +2.3% | — |
| Nov 5, 2024 | AMC | 0.68 | 0.69 | +1.5% | 82.53 | +5.9% | +17.7% | -1.9% | -0.2% | -0.5% | -2.7% | — |
| Aug 13, 2024 | AMC | 0.81 | 0.73 | -9.9% | 90.00 | -7.8% | -9.3% | +1.8% | +1.3% | -0.2% | -2.7% | — |
| May 7, 2024 | AMC | 0.56 | 0.51 | -8.9% | 105.59 | -2.8% | -1.6% | +1.1% | +1.3% | -1.3% | +1.4% | — |
| Feb 28, 2024 | AMC | 0.57 | 0.59 | +3.5% | 99.87 | +2.2% | +6.4% | -1.6% | +1.0% | -1.6% | +1.0% | — |
| Nov 7, 2023 | AMC | 0.62 | 0.62 | +0.0% | 85.25 | -5.0% | -2.9% | -2.7% | +2.2% | -0.1% | +6.0% | — |
| Aug 8, 2023 | AMC | 0.75 | 0.76 | +1.3% | 120.02 | -3.8% | -9.2% | +1.1% | -0.6% | -2.3% | -1.9% | — |
| May 3, 2023 | AMC | 0.52 | 0.59 | +13.5% | 106.38 | +1.1% | +2.0% | +5.2% | +0.2% | -3.6% | +2.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 | Barrington Research | Reiterates | Outperform | $90 | $60.85 | $59.94 | -1.5% | -1.2% | +8.2% | -3.5% | +3.6% | -5.3% |
| Feb 20 | Barrington Research | Maintains | Outperform → Outperform | — | $86.45 | $86.22 | -0.3% | -1.6% | -1.8% | -0.8% | -1.4% | -2.9% |
| Jan 5 | Barrington Research | Maintains | Outperform → Outperform | — | $78.88 | $79.73 | +1.1% | +6.8% | -3.5% | -2.2% | +2.5% | +3.0% |
| Nov 24 | JP Morgan | Maintains | Overweight → Overweight | — | $71.63 | $72.00 | +0.5% | -0.2% | +3.7% | -0.3% | -0.1% | -0.4% |
| Oct 24 | Barrington Research | Maintains | Outperform → Outperform | — | $91.34 | $92.55 | +1.3% | +2.0% | -2.3% | -1.2% | -2.1% | -2.1% |
| Aug 8 | Barrington Research | Maintains | Outperform → Outperform | — | $83.75 | $83.02 | -0.9% | +4.7% | -1.1% | +0.9% | +1.2% | -2.9% |
| Jul 1 | Barrington Research | Maintains | Outperform → Outperform | — | $78.20 | $77.90 | -0.4% | +3.1% | +0.1% | +1.8% | -3.4% | -3.3% |
| Apr 22 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $66.31 | $67.39 | +1.6% | +2.4% | +1.3% | +1.4% | +1.2% | +1.0% |
| Mar 19 | JP Morgan | Maintains | Overweight → Overweight | — | $76.17 | $76.28 | +0.1% | -0.2% | -1.8% | -2.5% | +1.2% | -0.5% |
| Feb 28 | Barrington Research | Maintains | Outperform → Outperform | — | $82.42 | $82.63 | +0.3% | -1.7% | -1.7% | -0.3% | +2.3% | +2.1% |
| Dec 16 | BofA Securities | Upgrade | Neutral → Buy | — | $93.46 | $96.21 | +2.9% | +2.2% | -0.6% | -2.7% | -1.1% | -0.1% |
| Dec 3 | JP Morgan | Maintains | Overweight → Overweight | — | $99.37 | $100.65 | +1.3% | -0.4% | +0.9% | -2.3% | -1.6% | +0.4% |
| Nov 21 | Barrington Research | Maintains | Outperform → Outperform | — | $94.06 | $94.22 | +0.2% | +3.1% | +0.9% | +0.2% | +0.6% | -1.5% |
| Nov 7 | Barrington Research | Maintains | Outperform → Outperform | — | $97.10 | $96.66 | -0.5% | -1.9% | -0.2% | -0.5% | -2.7% | -0.2% |
| Oct 9 | Barrington Research | Maintains | Outperform → Outperform | — | $77.48 | $76.89 | -0.8% | +0.9% | -0.9% | +3.6% | +2.0% | +0.5% |
| Oct 7 | BofA Securities | Downgrade | Buy → Neutral | — | $81.05 | $78.73 | -2.9% | -3.2% | -1.3% | +0.9% | -0.9% | +3.6% |
| Sep 20 | Barrington Research | Maintains | Outperform → Outperform | — | $85.02 | $85.41 | +0.5% | -2.0% | -0.3% | +1.0% | +0.5% | -0.1% |
| Aug 15 | Barrington Research | Maintains | Outperform → Outperform | — | $81.64 | $83.23 | +1.9% | +1.8% | +1.3% | -0.2% | -2.7% | +1.6% |
| May 9 | Barrington Research | Maintains | Outperform → Outperform | — | $103.92 | $103.79 | -0.1% | +1.1% | +1.3% | -1.3% | +1.4% | +1.5% |
| Mar 13 | JP Morgan | Maintains | Overweight → Overweight | — | $106.26 | $107.00 | +0.7% | +1.3% | -1.0% | +0.1% | +0.3% | +2.0% |
| Mar 1 | Barrington Research | Maintains | Outperform → Outperform | — | $106.27 | $106.58 | +0.3% | -1.6% | +1.0% | -1.6% | +1.0% | +0.3% |
| Jan 3 | Barrington Research | Maintains | Outperform → Outperform | — | $93.47 | $93.47 | +0.0% | -1.2% | +1.1% | -0.6% | +1.6% | -0.7% |
| Nov 17 | JP Morgan | Maintains | Overweight → Overweight | — | $85.37 | $85.73 | +0.4% | -0.8% | +1.6% | -1.1% | +2.6% | +0.8% |
| Nov 9 | Barrington Research | Maintains | Outperform → Outperform | — | $82.76 | $82.16 | -0.7% | -2.7% | +2.2% | -0.1% | +6.0% | -0.2% |
| Sep 19 | CJS Securities | Upgrade | Market Perform → Market Outperform | — | $94.86 | $94.80 | -0.1% | +0.8% | +0.9% | -1.8% | +0.6% | +1.7% |
| Aug 14 | Barrington Research | Maintains | Outperform → Outperform | — | $109.60 | $109.49 | -0.1% | -2.3% | -1.9% | -3.6% | +0.4% | +0.5% |
| May 5 | Barrington Research | Maintains | Outperform → Outperform | — | $108.49 | $110.00 | +1.4% | +5.2% | +0.2% | -3.6% | +2.8% | -1.6% |
| Feb 24 | Barrington Research | Maintains | Outperform → Outperform | — | $99.94 | $99.28 | -0.7% | -1.2% | +1.0% | +1.6% | +0.6% | -0.8% |
| Dec 14 | CJS Securities | Upgrade | Market Perform → Market Outperform | — | $93.90 | $93.56 | -0.4% | +1.4% | +0.6% | -1.7% | +3.3% | -3.1% |
| May 7 | Barrington Research | Upgrade | Market Perform → Outperform | — | $116.77 | $119.51 | +2.3% | +2.0% | -0.8% | -0.6% | -3.2% | +2.5% |
| May 3 | Jefferies | Upgrade | Hold → Buy | — | $112.45 | $115.99 | +3.1% | +4.6% | -1.3% | -3.1% | +3.8% | +2.0% |
| Feb 26 | Barrington Research | Downgrade | Outperform → Market Perform | — | $116.31 | $116.03 | -0.2% | +0.8% | -0.8% | -2.4% | -2.4% | -0.1% |
| Mar 27 | Sidoti & Co. | Maintains | Buy → Buy | — | $70.00 | $67.00 | -4.3% | -7.8% | +7.4% | -0.4% | -14.5% | +1.1% |
| Nov 8 | Barrington Research | Upgrade | Market Perform → Outperform | — | $119.18 | $119.20 | +0.0% | -1.4% | -0.4% | -0.0% | -3.0% | +1.6% |
| Nov 2 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $115.56 | $115.50 | -0.1% | -2.2% | +1.1% | +0.2% | +1.7% | -0.1% |
| May 4 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $90.00 | $87.90 | -2.3% | +0.7% | +1.0% | -0.1% | +0.6% | +0.0% |
| Nov 3 | Barrington Research | Downgrade | Outperform → Market Perform | — | $72.05 | $70.95 | -1.5% | -8.0% | +0.2% | -0.5% | +1.4% | +2.0% |
| Mar 17 | Barrington Research | Downgrade | Outperform → Market Perform | — | $69.90 | $69.40 | -0.7% | -2.5% | -0.4% | -4.6% | -0.9% | -1.8% |
| Nov 4 | Barrington Research | Upgrade | Market Perform → Outperform | — | $53.20 | $53.60 | +0.8% | +4.3% | +1.2% | +0.5% | +0.4% | +1.9% |
| Aug 5 | Jefferies | Maintains | Hold → Hold | — | $60.88 | $60.20 | -1.1% | +0.5% | -1.4% | +0.7% | -0.5% | +1.3% |
| May 6 | Barrington Research | Upgrade | Market Perform → Outperform | — | $51.83 | $51.91 | +0.2% | +9.0% | +3.3% | -1.0% | -0.3% | -1.1% |
| Mar 1 | Jefferies | Downgrade | Buy → Hold | — | $50.69 | $50.47 | -0.4% | -2.6% | +2.1% | +6.7% | -5.2% | +0.6% |
| May 6 | Barrington Research | Upgrade | Market Perform → Outperform | — | $44.99 | $43.55 | -3.2% | +0.1% | +2.3% | +5.5% | +1.1% | -1.4% |
| Oct 28 | Jefferies | Maintains | Buy → Buy | — | $39.54 | $39.45 | -0.2% | +4.6% | +1.9% | +1.9% | +0.4% | +0.3% |
| Dec 17 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $34.18 | $33.84 | -1.0% | -0.3% | +1.4% | -0.6% | +1.3% | +0.4% |
| Aug 12 | Noble Capital Markets | Downgrade | Buy → Hold | — | $31.24 | $30.74 | -1.6% | -0.9% | -0.0% | -1.0% | -4.6% | -0.2% |
| Aug 12 | Noble Financial | Downgrade | Buy → Hold | — | $31.24 | $30.74 | -1.6% | -0.9% | -0.0% | -1.0% | -4.6% | -0.2% |
| Mar 8 | Noble Capital Markets | Upgrade | Hold → Buy | — | $22.89 | $23.61 | +3.1% | +2.5% | -0.7% | +0.7% | +0.6% | +1.0% |
| Mar 8 | Noble Financial | Upgrade | Hold → Buy | — | $22.89 | $23.61 | +3.1% | +2.5% | -0.7% | +0.7% | +0.6% | +1.0% |
| Jan 10 | Noble Capital Markets | Downgrade | Buy → Hold | — | $25.38 | $25.18 | -0.8% | -3.4% | +2.0% | -0.5% | +0.9% | +1.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Minan Peter Francis | — | Buy | 288 | $61.50 | $18K | 3,211 | +4.71% | -5.35% |
| Jun 8, 2026 | Minan Peter Francis | — | Buy | 492 | $63.14 | $31K | 2,923 | +4.71% | -5.35% |
8-K
U.S. Physical Therapy, Inc. -- 8-K Filing
May 19
8-K · 7.01
! Medium
U.S. Physical Therapy, Inc. -- 8-K 7.01: Regulation FD Disclosure
U.S. Physical Therapy (USPH) disclosed Q1 2026 earnings results through a conference call, providing investors with updates on its outpatient clinic operations and industrial injury prevention services performance.
May 11
— 8-K filing (BAC, USPH)
Apr 15
— 8-K filing (BAC, USPH)
Apr 15
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
Bank of America secured $125 million in financing, potentially strengthening liquidity and reducing borrowing costs, which could improve profitability and support shareholder returns.
Apr 15
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
This dividend equivalent structure on restricted stock units protects equity compensation value during vesting periods, but investors should monitor whether excessive RSU grants dilute shareholder ownership and future earnings per share.
Mar 13
8-K · 7.01
! Medium
US Physical Therapy Inc -- 8-K 7.01: Regulation FD Disclosure
US Physical Therapy updated its investor presentation to provide stakeholders with current information about its outpatient clinic operations and industrial injury prevention services business.
Mar 9
8-K · 7.01
! Medium
US Physical Therapy Inc -- 8-K 7.01: Regulation FD Disclosure
US Physical Therapy disclosed 2025 fourth-quarter and full-year financial results via conference call, providing investors with management commentary on operational performance and business outlook.
Mar 3
8-K · 5.02
!!! Very High
US Physical Therapy Inc -- 8-K 5.02: Executive Change
US Physical Therapy Inc (USPH) lost director Carey Hendrickson through resignation, reducing board oversight depth without specified succession details.
Feb 26
8-K · 8.01
!! High
US Physical Therapy Inc -- 8-K 8.01: Material Event / Announcement
US Physical Therapy's Metro Physical Therapy subsidiary established a 10-year strategic alliance with NYU Langone Health to provide physical therapy services across Long Island and the New York metropolitan area, expanding its market reach.
Feb 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 2,006,666 | $157M | Reduced | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 664,062 | $50M | New | Mar 2026 |
| 3 | Bank Of America Corp /de/ | 554,621 | $42M | Added | Mar 2026 |
| 4 | Boston Trust Walden Corp | 400,109 | $30M | Reduced | Mar 2026 |
| 5 | William Blair Investment Management, Llc | 377,863 | $28M | Added | Mar 2026 |
| 6 | Vanguard Portfolio Management Llc | 312,309 | $23M | New | Mar 2026 |
| 7 | Schroder Investment Management Group | 256,515 | $19M | Reduced | Mar 2026 |
| 8 | Point72 Asset Management | 241,402 | $18M | Reduced | Mar 2026 |
| 9 | Northern Trust Corp | 210,928 | $16M | Reduced | Mar 2026 |
| 10 | Fmr Llc | 148,034 | $11M | Added | Mar 2026 |
| 11 | Rbf Capital, Llc | 139,998 | $10M | — | Mar 2026 |
| 12 | Rockefeller Capital Management L.p. | 134,140 | $10M | Reduced | Mar 2026 |
| 13 | Royal Bank Of Canada | 133,777 | $10M | Added | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 131,676 | $10M | Reduced | Mar 2026 |
| 15 | Wells Fargo & Company/mn | 126,168 | $9M | New | Mar 2026 |
| 16 | Sei Investments Co | 118,323 | $9M | Added | Mar 2026 |
| 17 | Two Sigma Investments, Lp | 102,567 | $8M | Added | Mar 2026 |
| 18 | Jpmorgan Chase & Co | 96,995 | $7M | Reduced | Mar 2026 |
| 19 | Principal Financial Group Inc | 88,574 | $7M | Added | Dec 2025 |
| 20 | Ubs Group Ag | 84,719 | $6M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$960.9M
Enterprise Value
$1.19B
P/E (TTM)
44.59x
Forward P/E
22.14x
PEG Ratio
-3.45x
P/B
1.25x
P/S
1.23x
P/FCF
15.76x
EV/EBITDA
10.84x
Shares Out
15.2M
Financials (TTM)
Revenue
$781.0M
Net Income
$15.1M
EBITDA
$109.7M
Free Cash Flow
$61.0M
Op Cash Flow
$75.1M
EPS Basic
$1.42
EPS Diluted
$1.42
EPS Forward
$2.86
Gross Margin
20.2%
Op Margin
10.3%
Net Margin
1.9%
Balance Sheet
Total Assets
$1.20B
Total Liab.
$433.8M
Total Equity
$769.7M
Cash
$35.6M
LT Debt
$263.2M
Book Value/Sh
$50.75
Debt/Equity
0.89x
Current Ratio
1.01
Quick Ratio
1.01
Returns & Growth
ROE
8.3%
ROA
3.3%
ROIC
5.4%
Rev Growth YoY
+16.3%
EPS Growth YoY
-22.8%
Price Returns
2W
-1.3%
1M
-9.8%
3M
-22.5%
6M
-13.0%
12M
-14.3%
Technicals
52W High
$93.16
52W Low
$59.00
50d MA
$67.48
200d MA
$77.89
RSI (14)
47.10
ATR (14)
$2.30
Beta
1.35
Avg Volume
249K
Dividends
Div Rate
$1.80
Div Yield
2.5%
Frequency
4
Ex-Div Date
Mar 13, 2026
Analyst Price Targets
Consensus
$102.00
High
$102.00
Low
$102.00
Median
$102.00
Data updated apr 27, 2026 7:09am
· Source: financialmodelingprep.com